GlassScriptPhysician profile
Hishani Perera
NPI 1699184283
$3,996.04
in general payments reported to CMS, 2019-2025
25 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $70.08 · 2022: $553 · 2023: $778 · 2024: $1,202 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,372.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $774.30 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $584.89 | 2022-2025 | Airsupra, Breztri, Tezspire |
| Abbvie INC. | $493.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $245.31 | 2024 | Xarelto |
| Pfizer INC. | $212.51 | 2023-2025 | |
| Lilly USA, LLC | $177.63 | 2024-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.37 | 2022-2024 | Xifaxan |
| Sandoz INC. | $140.87 | 2025 | |
| Amgen INC. | $137.67 | 2023-2025 | Repatha, Evenity, Otezla |
| Exact Sciences Corporation | $125.66 | 2023-2025 | Cologuard Collection Kit |
| Paratek Pharmaceuticals, INC. | $125.00 | 2023 | Nuzyra |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Vifor Pharma, INC. | $125.00 | 2025 | Veltassa |
| Vertex Pharmaceuticals Incorporated | $117.60 | 2025 | |
| Neurocrine Biosciences, INC. | $117.19 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59.39 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Philips North America LLC | $58.34 | 2024 | (Ck6) Holter |
| Myriad Genetic Laboratories, INC. | $39.12 | 2023 | Colaris |
| Bayer Healthcare Pharmaceuticals INC. | $27.27 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.82 | 2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $26.64 | 2025 | Opsumit, Uptravi |
| Csl Behring | $25.09 | 2024 | Kcentra |
| Abbott Laboratories | $24.38 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $24.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.05 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hishani Perera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.